<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), 86 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) evolving from <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and six patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> after previous chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Median age was 58 years (range: 18-76 years) </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, ara-C, and <z:chebi fb="0" ids="4911">etoposide</z:chebi>, 52% of them aged &lt;/=60 years and 35% aged &gt;60 years (p=0.06) </plain></SENT>
<SENT sid="3" pm="."><plain>After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2 </plain></SENT>
<SENT sid="4" pm="."><plain>Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19% </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival of <z:hpo ids='HP_0000001'>all</z:hpo> patients was 8 months, and 21 months for the CR patients </plain></SENT>
<SENT sid="7" pm="."><plain>Median survival was significantly longer among patients aged &lt;/=60 years than among the older patients (16 vs 6 months, p&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Median duration of survival and relapse-free survival were not statistically different in the two IL-2 treatment arms </plain></SENT>
</text></document>